AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Fiserv, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 filing for Y-mAbs Therapeutics (YMAB) discloses that director Laura Hamill received new equity awards on 30 June 2025.

  • Restricted Stock Units: 25,080 RSUs granted at no cost. The award vests in full on the earlier of 12 months after grant or immediately before the 2026 annual shareholder meeting, subject to continued service.
  • Stock Options: 33,450 options with a US$4.51 exercise price, expiring 30 June 2035. Vest in equal monthly instalments over one year and become exercisable upon vesting.
  • Post-transaction ownership: Hamill now directly holds 30,905 YMAB common shares and 33,450 vested/unvested options.

The transactions reflect routine director compensation under the 2018 Equity Incentive Plan and do not involve open-market purchases or sales.

La dichiarazione del Modulo 4 per Y-mAbs Therapeutics (YMAB) rivela che la direttrice Laura Hamill ha ricevuto nuovi premi azionari il 30 giugno 2025.

  • Unità di Azioni Vincolate (RSU): 25.080 RSU assegnate gratuitamente. Il premio matura completamente al più presto tra 12 mesi dalla concessione o immediatamente prima dell'assemblea annuale degli azionisti del 2026, subordinatamente al mantenimento del servizio.
  • Opzioni Azionarie: 33.450 opzioni con prezzo di esercizio di 4,51 USD, scadenza il 30 giugno 2035. Maturano in rate mensili uguali nell'arco di un anno e diventano esercitabili al momento della maturazione.
  • Proprietà dopo la transazione: Hamill detiene ora direttamente 30.905 azioni ordinarie YMAB e 33.450 opzioni maturate/non maturate.

Le transazioni riflettono la compensazione ordinaria dei direttori secondo il Piano di Incentivi Azionari 2018 e non coinvolgono acquisti o vendite sul mercato aperto.

La presentación del Formulario 4 para Y-mAbs Therapeutics (YMAB) revela que la directora Laura Hamill recibió nuevas concesiones de acciones el 30 de junio de 2025.

  • Unidades de Acciones Restringidas (RSU): 25,080 RSU otorgadas sin costo. La concesión se consolida en su totalidad al cumplirse 12 meses desde la adjudicación o inmediatamente antes de la reunión anual de accionistas de 2026, lo que ocurra primero, sujeto a la continuidad del servicio.
  • Opciones sobre Acciones: 33,450 opciones con un precio de ejercicio de 4,51 USD, que expiran el 30 de junio de 2035. Se consolidan en cuotas mensuales iguales durante un año y pueden ejercerse al consolidarse.
  • Propiedad después de la transacción: Hamill ahora posee directamente 30,905 acciones comunes de YMAB y 33,450 opciones consolidadas/no consolidadas.

Las transacciones reflejan la compensación habitual para directores bajo el Plan de Incentivos de Capital de 2018 y no implican compras o ventas en el mercado abierto.

Y-mAbs Therapeutics (YMAB)ì� Form 4 제출ì—� 따르ë©� ì´ì‚¬ì� Laura Hamillì� 2025ë…� 6ì›� 30ì¼ì— 새로ìš� ì£¼ì‹ ë³´ìƒì� 받았습니ë‹�.

  • 제한 ì£¼ì‹ ë‹¨ìœ„(RSU): 비용 ì—†ì´ ë¶€ì—¬ëœ 25,080 RSU. ë³´ìƒì€ ë¶€ì—� í›� 12개월ì� 경과하거ë‚� 2026ë…� ì—°ë¡€ 주주ì´íšŒ ì§ì „ ì¤� 빠른 시ì ì—� ì „ì•¡ ì·¨ë“ë˜ë©°, ê³„ì† ê·¼ë¬´ ì¡°ê±´ì� ì ìš©ë©ë‹ˆë‹�.
  • ì£¼ì‹ ë§¤ìˆ˜ì„ íƒê¶�: 행사 ê°€ê²� 4.51달러, 만기ì� 2035ë…� 6ì›� 30ì¼ì¸ 33,450 옵션. 1ë…� ë™ì•ˆ 매월 균등 ë¶„í• ë¡� ì·¨ë“ë˜ë©°, ì·¨ë“ ì‹� 행사í•� ìˆ� 있습니다.
  • 거래 í›� 보유 현황: Hamillì€ í˜„ìž¬ ì§ì ‘ì ìœ¼ë¡� 30,905ì£¼ì˜ YMAB 보통주와 33,450ì£¼ì˜ ì·¨ë“/미취ë“� 옵션ì� 보유하고 있습니다.

ì� 거래ëŠ� 2018ë…� ì£¼ì‹ ì¸ì„¼í‹°ë¸Œ 계íšì—� 따른 ì´ì‚¬ ë³´ìƒìœ¼ë¡œ ì¼ìƒì ì¸ 것ì´ë©�, 공개 시장ì—서ì� 매매ëŠ� í¬í•¨ë˜ì§€ 않습니다.

Le dépôt du formulaire 4 pour Y-mAbs Therapeutics (YMAB) révèle que la directrice Laura Hamill a reçu de nouvelles attributions d'actions le 30 juin 2025.

  • Unités d’Actions Restreintes (RSU) : 25 080 RSU attribuées sans coût. L’attribution est entièrement acquise au plus tôt 12 mois après l’octroi ou immédiatement avant l’assemblée générale annuelle 2026, sous réserve de la poursuite du service.
  • Options d’Achat d’Actions : 33 450 options avec un prix d’exercice de 4,51 USD, expirant le 30 juin 2035. Elles acquièrent des droits par versements mensuels égaux sur un an et deviennent exerçables à l’acquisition.
  • Possession après la transaction : Hamill détient désormais directement 30 905 actions ordinaires YMAB ainsi que 33 450 options acquises/non acquises.

Ces transactions reflètent une rémunération habituelle des administrateurs selon le Plan d’Incitation en Actions de 2018 et n’impliquent pas d’achats ou ventes sur le marché ouvert.

Formular 4 Einreichung für Y-mAbs Therapeutics (YMAB) zeigt, dass die Direktorin Laura Hamill am 30. Juni 2025 neue Aktienzuteilungen erhalten hat.

  • Restricted Stock Units (RSUs): 25.080 RSUs wurden kostenlos gewährt. Die Zuteilung erfolgt vollständig zum früheren Zeitpunkt von 12 Monaten nach Gewährung oder unmittelbar vor der Jahreshauptversammlung 2026, vorbehaltlich des fortgesetzten Dienstes.
  • Aktienoptionen: 33.450 Optionen mit einem Ausübungspreis von 4,51 USD, Laufzeit bis 30. Juni 2035. Sie werden in gleichen monatlichen Raten über ein Jahr erworben und können bei Erwerb ausgeübt werden.
  • Eigentum nach der Transaktion: Hamill hält nun direkt 30.905 YMAB-Stammaktien sowie 33.450 ausgeübte/nicht ausgeübte Optionen.

Die Transaktionen spiegeln die routinemäßige Vergütung von Direktoren gemäß dem Equity Incentive Plan 2018 wider und beinhalten keine Käufe oder Verkäufe am offenen Markt.

Positive
  • None.
Negative
  • None.

Insights

TL;DR � Routine equity grants; negligible impact on YMAB valuation.

The filing records standard annual equity compensation for a non-executive director. No shares were bought or sold in the market; therefore, no immediate cash flow effect on the company and no strong signalling value regarding insider sentiment. Grants align the director’s incentives with shareholders but are immaterial relative to YMAB’s ~41 million shares outstanding. Overall investor impact is neutral.

La dichiarazione del Modulo 4 per Y-mAbs Therapeutics (YMAB) rivela che la direttrice Laura Hamill ha ricevuto nuovi premi azionari il 30 giugno 2025.

  • Unità di Azioni Vincolate (RSU): 25.080 RSU assegnate gratuitamente. Il premio matura completamente al più presto tra 12 mesi dalla concessione o immediatamente prima dell'assemblea annuale degli azionisti del 2026, subordinatamente al mantenimento del servizio.
  • Opzioni Azionarie: 33.450 opzioni con prezzo di esercizio di 4,51 USD, scadenza il 30 giugno 2035. Maturano in rate mensili uguali nell'arco di un anno e diventano esercitabili al momento della maturazione.
  • Proprietà dopo la transazione: Hamill detiene ora direttamente 30.905 azioni ordinarie YMAB e 33.450 opzioni maturate/non maturate.

Le transazioni riflettono la compensazione ordinaria dei direttori secondo il Piano di Incentivi Azionari 2018 e non coinvolgono acquisti o vendite sul mercato aperto.

La presentación del Formulario 4 para Y-mAbs Therapeutics (YMAB) revela que la directora Laura Hamill recibió nuevas concesiones de acciones el 30 de junio de 2025.

  • Unidades de Acciones Restringidas (RSU): 25,080 RSU otorgadas sin costo. La concesión se consolida en su totalidad al cumplirse 12 meses desde la adjudicación o inmediatamente antes de la reunión anual de accionistas de 2026, lo que ocurra primero, sujeto a la continuidad del servicio.
  • Opciones sobre Acciones: 33,450 opciones con un precio de ejercicio de 4,51 USD, que expiran el 30 de junio de 2035. Se consolidan en cuotas mensuales iguales durante un año y pueden ejercerse al consolidarse.
  • Propiedad después de la transacción: Hamill ahora posee directamente 30,905 acciones comunes de YMAB y 33,450 opciones consolidadas/no consolidadas.

Las transacciones reflejan la compensación habitual para directores bajo el Plan de Incentivos de Capital de 2018 y no implican compras o ventas en el mercado abierto.

Y-mAbs Therapeutics (YMAB)ì� Form 4 제출ì—� 따르ë©� ì´ì‚¬ì� Laura Hamillì� 2025ë…� 6ì›� 30ì¼ì— 새로ìš� ì£¼ì‹ ë³´ìƒì� 받았습니ë‹�.

  • 제한 ì£¼ì‹ ë‹¨ìœ„(RSU): 비용 ì—†ì´ ë¶€ì—¬ëœ 25,080 RSU. ë³´ìƒì€ ë¶€ì—� í›� 12개월ì� 경과하거ë‚� 2026ë…� ì—°ë¡€ 주주ì´íšŒ ì§ì „ ì¤� 빠른 시ì ì—� ì „ì•¡ ì·¨ë“ë˜ë©°, ê³„ì† ê·¼ë¬´ ì¡°ê±´ì� ì ìš©ë©ë‹ˆë‹�.
  • ì£¼ì‹ ë§¤ìˆ˜ì„ íƒê¶�: 행사 ê°€ê²� 4.51달러, 만기ì� 2035ë…� 6ì›� 30ì¼ì¸ 33,450 옵션. 1ë…� ë™ì•ˆ 매월 균등 ë¶„í• ë¡� ì·¨ë“ë˜ë©°, ì·¨ë“ ì‹� 행사í•� ìˆ� 있습니다.
  • 거래 í›� 보유 현황: Hamillì€ í˜„ìž¬ ì§ì ‘ì ìœ¼ë¡� 30,905ì£¼ì˜ YMAB 보통주와 33,450ì£¼ì˜ ì·¨ë“/미취ë“� 옵션ì� 보유하고 있습니다.

ì� 거래ëŠ� 2018ë…� ì£¼ì‹ ì¸ì„¼í‹°ë¸Œ 계íšì—� 따른 ì´ì‚¬ ë³´ìƒìœ¼ë¡œ ì¼ìƒì ì¸ 것ì´ë©�, 공개 시장ì—서ì� 매매ëŠ� í¬í•¨ë˜ì§€ 않습니다.

Le dépôt du formulaire 4 pour Y-mAbs Therapeutics (YMAB) révèle que la directrice Laura Hamill a reçu de nouvelles attributions d'actions le 30 juin 2025.

  • Unités d’Actions Restreintes (RSU) : 25 080 RSU attribuées sans coût. L’attribution est entièrement acquise au plus tôt 12 mois après l’octroi ou immédiatement avant l’assemblée générale annuelle 2026, sous réserve de la poursuite du service.
  • Options d’Achat d’Actions : 33 450 options avec un prix d’exercice de 4,51 USD, expirant le 30 juin 2035. Elles acquièrent des droits par versements mensuels égaux sur un an et deviennent exerçables à l’acquisition.
  • Possession après la transaction : Hamill détient désormais directement 30 905 actions ordinaires YMAB ainsi que 33 450 options acquises/non acquises.

Ces transactions reflètent une rémunération habituelle des administrateurs selon le Plan d’Incitation en Actions de 2018 et n’impliquent pas d’achats ou ventes sur le marché ouvert.

Formular 4 Einreichung für Y-mAbs Therapeutics (YMAB) zeigt, dass die Direktorin Laura Hamill am 30. Juni 2025 neue Aktienzuteilungen erhalten hat.

  • Restricted Stock Units (RSUs): 25.080 RSUs wurden kostenlos gewährt. Die Zuteilung erfolgt vollständig zum früheren Zeitpunkt von 12 Monaten nach Gewährung oder unmittelbar vor der Jahreshauptversammlung 2026, vorbehaltlich des fortgesetzten Dienstes.
  • Aktienoptionen: 33.450 Optionen mit einem Ausübungspreis von 4,51 USD, Laufzeit bis 30. Juni 2035. Sie werden in gleichen monatlichen Raten über ein Jahr erworben und können bei Erwerb ausgeübt werden.
  • Eigentum nach der Transaktion: Hamill hält nun direkt 30.905 YMAB-Stammaktien sowie 33.450 ausgeübte/nicht ausgeübte Optionen.

Die Transaktionen spiegeln die routinemäßige Vergütung von Direktoren gemäß dem Equity Incentive Plan 2018 wider und beinhalten keine Käufe oder Verkäufe am offenen Markt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DE CASTRO HENRIQUE

(Last) (First) (Middle)
600 N. VEL R. PHILLIPS AVENUE

(Street)
MILWAUKEE WI 53203

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
FISERV INC [ FI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Deferred Compensation Notional Units (1) 06/30/2025 A 189 (1) (1) Common Stock 189 $172.41(1) 4,857 D
Explanation of Responses:
1. These deferred compensation notional units were allocated under the Fiserv, Inc. Non-Employee Director Deferred Compensation Plan (the "Plan"), under which director fees otherwise payable in cash may be deferred in exchange for the allocation of notional units under the Plan. This Form 4 reports the crediting of units under the Plan on June 30, 2025, in respect of $32,500 of deferred compensation. The number of notional units credited is calculated by dividing the amount of compensation that is deferred by the closing price of the company's common stock on the date of deferral, or last business day prior. On June 30, 2025, the closing price of Fiserv's common stock was $172.41 per share. Following cessation of the reporting person's service to the company, each notional unit will be settled in shares of Fiserv common stock on a one-for-one basis.
Remarks:
/s/ Eric C. Nelson (attorney-in-fact) 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did YMAB director Laura Hamill receive on 30 June 2025?

She was granted 25,080 RSUs and 33,450 stock options with a US$4.51 exercise price.

When do the 25,080 RSUs granted to Laura Hamill vest?

They vest in full on the earlier of one year after grant or immediately before YMAB’s 2026 annual meeting, subject to continued service.

What is the exercise window for the 33,450 options issued to Laura Hamill?

The options vest monthly over one year and are exercisable upon vesting, expiring on 30 June 2035.

How many YMAB common shares does Laura Hamill own after the reported transactions?

She directly owns 30,905 shares of YMAB common stock.

Did the Form 4 indicate any open-market purchase or sale of YMAB shares?

No. The filing only shows equity awards; there were no open-market transactions.
Fiserv Inc

NYSE:FI

FI Rankings

FI Latest News

FI Latest SEC Filings

FI Stock Data

95.01B
550.25M
0.68%
94.13%
1.49%
Information Technology Services
Services-business Services, Nec
United States
MILWAUKEE